Immunotherapeutic Approaches for the Control and Eradication of HIV

References

• Azzoni L, Foulkes AS, Papasavvas E, et al. (2013). Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis, 207, 213–22
   PubMed Web of Science ®Google Scholar
• Barouch DH, Deeks SG. (2014). Immunologic strategies for HIV-1 remission and eradication. Science, 345, 169–74
   PubMed Web of Science ®Google Scholar
• Bartesaghi A, Merk A, Borgnia MJ, et al. (2013). Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol, 20, 1352–7
   PubMed Web of Science ®Google Scholar
• Burton DR, Poignard P, Stanfield RL, et al. (2012). Broadly neutralizing antibodies project new prospects to highly antigenically diverse viruses. Science, 337, 183–6
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. (1981). Pneumocystis pneumonia. MMWR, 30, 1–3
   Google Scholar
• Center for Disease Control and Prevention. (2015). Prevalence of diagnosed and undiagnosed HIV infection: 2008–2012. MMWR, 64, 657–62
   PubMed Web of Science ®Google Scholar
• Checkley MA, Luttge BG, Freed EO. (2011). HIV-1 envelope glycoprotein biosynthesis, trafficking and incorporation. J Mol Biol, 410, 582–608
   PubMed Web of Science ®Google Scholar
• Chomont N, El-Far M, Ancuta P, et al. (2009). HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med, 15, 893–900
   PubMed Web of Science ®Google Scholar
• Chun TW, Stuyver L, Mizell SB, et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA, 94, 13193–7
   PubMed Web of Science ®Google Scholar
• Davies J, Jiang I, Pan LZ, et al. (2001). Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng, 74, 288–94
   PubMed Web of Science ®Google Scholar
• Deeks SG. (2012). HIV: Shock and kill. Nature, 487, 439–40
   PubMed Web of Science ®Google Scholar
• de Veer MJ, Holko M, Frevel M, et al. (2001). Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol, 69, 912–20
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Schramm CA, Gorman J, et al. (2014). Developmental pathway for potent V1V2-directed HIV neutralizing antibodies. Nature, 509, 55–62
   PubMed Web of Science ®Google Scholar
• Duffy S, Shackelton LA, Holmes EC. (2008). Rates of evolutionary change in viruses: Patterns and determinant. Nat Rev Gen, 9, 267–76
   PubMed Web of Science ®Google Scholar
• Euler Z, Alter G. (2015). Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AID Res Human Retroviruses, 31, 13–24
   PubMed Web of Science ®Google Scholar
• Falkowska E, Lo KM, Ramos A, et al. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the perfusion conformation of gp41 on cleaved envelope trimers. Immunity, 40, 657–68
   PubMed Web of Science ®Google Scholar
• Fauci AS. (2007). Pathogenesis of HIV disease: Opportunities for new prevention interventions. Clin Infect Dis, 45, S206–12
   Google Scholar
• Finzi D, Hermankoya M, Pierson T, et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295–300
   PubMed Web of Science ®Google Scholar
• French AR, Yokoyama WM. (2003). Natural killer cells and viral infections. Curr Opin Immunol, 15, 45–51
   PubMed Web of Science ®Google Scholar
• Fry TJ, Mackall CL. (2001). What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function. AIDS, 15, 1881–2
   PubMed Web of Science ®Google Scholar
• Garcia F, Climent N, Assoumou L, et al. (2011). A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis, 203, 473–8
   PubMed Web of Science ®Google Scholar
• Garcia F, Leon A, Gatell JM, et al. (2012). Therapeutic vaccines against HIV infection. Hum Vaccin Immunother, 8, 569–81
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. (2014). Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med, 370, 1101–10
   PubMed Web of Science ®Google Scholar
• Guttman M, Garcia NK, Cupo A, et al. (2014). CD4-induced activation in a soluble HIV-1 Env trimer. Structure, 22, 974–84
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hu Z, Li JZ, et al. (2013). Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis, 207, 1694–702
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner, M, et al. (2009). Long-term control of HIV by CCR5 Delta 32/Delta 32 stem-cell transplantation. N Engl J Med, 360, 692–8
   PubMed Web of Science ®Google Scholar
• INSIGHT-ESPRIT Study Group. SILCAAT Scientific Committee. (2009). Interleukin-2 therapy in patients with HIV infection. N Eng J Med, 361, 1548–59
   PubMed Web of Science ®Google Scholar
• Jacobson EL, Pilaro F, Smith KA. (1997). Interleukin-2 infusions in HIV infected patients. N Eng J Med, 336, 1260–1
   PubMed Web of Science ®Google Scholar
• Jain V, Hartogensis W, Bacchetti P, et al. (2013). Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis, 208, 1202–11
   PubMed Web of Science ®Google Scholar
• Kulpa DA, Lawani M, Cooper A, et al. (2013). PD-1 coinhibitory signals: The link between pathogenesis and protection. Semin Immunol, 25, 219–27
   PubMed Web of Science ®Google Scholar
• Kwong PD, Mascola JR. (2012). Human antibodies that neutralize HIV-1: Identification structures, and B cell ontogenies. Immunity, 37, 412–25
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, et al. (2013). Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 496, 469–76
   PubMed Web of Science ®Google Scholar
• Lyumkis D, Julien JP, de Val N, et al. (2013). Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science, 342, 1484–90
   PubMed Web of Science ®Google Scholar
• Mascola JR. (2015). The modern era of HIV-1 vaccine development. Science, 349, 139–40
   PubMed Web of Science ®Google Scholar
• McCoy LE, Weiss RA. (2013). Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med, 210, 209–23
   PubMed Web of Science ®Google Scholar
• Moore PI, Crooks ET, Porter I, et al. (2006). Nature of non-functional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol, 80, 2515–28
   PubMed Web of Science ®Google Scholar
• Mouquet H. (2014). Antibody B cell responses in HIV-1 infection. Trends Immunol, 35, 549–61
   PubMed Web of Science ®Google Scholar
• North TW, Higgins J, Deere JD, et al. (2010). Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol, 84, 2913–22
   PubMed Web of Science ®Google Scholar
• Persaud D, Zhou Y, Siliciano JM, et al. (2003). Latency in human immunodeficiency virus type 1 infection: No easy answers. J Virol, 77, 1659–65
   PubMed Web of Science ®Google Scholar
• Poignard P, Moulard M, Golez B, et al. (2003). Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and non-neutralizing antibodies. J Virol, 77, 353–65
   PubMed Web of Science ®Google Scholar
• Pollara J, Bonsignori M, Moody MA, et al. (2013). Epitope specificity of human immunodeficiency virus type 1 antibody dependent cellular cytotoxicity (ADCC) responses. Curr HIV Res, 11, 378–87
   PubMed Web of Science ®Google Scholar
• Porichis F, Kaufmann DE. (2012). Role of PD-1 in HIV-1 pathogenesis and as target for therapy. Curr HIV/AIDS Rep, 9, 8190
   Google Scholar
• Reguzova AY, Karpenko LI, Mechetina LV, et al. (2015). Peptide-MHC multimer-based monitoring of CD8 T cells in HIV-1 infection and AIDS vaccine development. Expert Rev Vaccines, 14, 69–84
   PubMed Web of Science ®Google Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux I, et al. (2013). Post-treatment HIV-1 controllers with a long term virological remission after the interruption of early initiated anti-retroviral therapy: ANRS VISCONTI Study. PLoS Pathog, 9, e1003211
   PubMed Web of Science ®Google Scholar
• Scharf I, Scheid JR, Lee JH, et al. (2014). Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep, 7, 785–95
   PubMed Web of Science ®Google Scholar
• Shan L, Deng K, Shroff NS, et al. (2012). Stimulation of HIV-1-specific cytolytic T lymphocyte facilitates elimination of latent viral reservoir after virus reactivation. Immunity, 36, 491–501
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Misaka H, et al. (2009). Non-fucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for Fc gamma RIIIb and MHC class II expression on the phagocytic neutrophils. Exp Hematol, 37, 309–21
   PubMed Web of Science ®Google Scholar
• Tae-Wook C, Lieven S, Mizell SB. (1997). Presence of an inducible HIV-1 latent reservoir during high active antiretroviral therapy. Proc Natl Acad Sci, 94, 13193–7
   PubMed Web of Science ®Google Scholar
• Yukl SA, Shergill AK, Ho T, et al. (2013). The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: Implications for viral persistence. PLoS Pathog, E100, 3347
   Google Scholar
• Zhang JY, Zhang Z, Wang XC, et al. (2007). PD-1 upregulation is correlated with HIV-specific memory CD8 (+) T cell exhaustion in typical progressors, but not in long-term non-progressors. Blood, 109, 4671–8
   PubMed Web of Science ®Google Scholar
• Zhou J, Cheung AKL, Tan Z, et al. (2015). PD-1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest, 123, 2629–42
   Web of Science ®Google Scholar
• Zolla-Pazner S. (2014). A critical question for HIV vaccine development: Which antibodies to induce? Science, 345, 167–8
   PubMed Web of Science ®Google Scholar